Fig. 5From: An N6-methyladenosine regulation- and mRNAsi-related prognostic index reveals the distinct immune microenvironment and immunotherapy responses in lower-grade gliomaThe 33 chemotherapeutic drugs, with significantly different IC50 between high- and low-risk groups, were identified by using "pRRophetic" package. Statistical test: Wilcoxon. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001Back to article page